Quetiapine is an antipsychotic drug used for the treatment of schizophrenia, bipolar disorder and depression and is currently marketed as a QD tablet. An alternate presentation of the drug in the form of controlled release microspheres would provide flexibility of finer dose titrations and address patients with dysphagia when delivered as a suspension.
Adare’s Optimμm® technology offers a unique and efficient method of fabricating monodisperse microparticles at reduced development time. The study herein uses Adare’s technology to fabricate monodisperse quetiapine microparticles to investigate the effects of formulation and size on the release profile of the API.